Breaking Down Bausch Health Companies Inc. (BHC) Financial Health: Key Insights for Investors

Breaking Down Bausch Health Companies Inc. (BHC) Financial Health: Key Insights for Investors

CA | Healthcare | Drug Manufacturers - Specialty & Generic | NYSE

Bausch Health Companies Inc. (BHC) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



Understanding Bausch Health Companies Inc. (BHC) Revenue Streams

Revenue Analysis

Financial performance for the company reveals key revenue insights for investors:

Revenue Metric 2023 Value 2022 Value Year-over-Year Change
Total Revenue $4.37 billion $4.63 billion -5.6%
International Revenue $1.82 billion $1.97 billion -7.5%
Domestic Revenue $2.55 billion $2.66 billion -4.1%

Revenue Stream Breakdown

  • Ophthalmology Segment: $1.64 billion
  • Neurology Segment: $1.22 billion
  • Dermatology Segment: $0.89 billion
  • Other Segments: $0.62 billion

Geographic Revenue Distribution

Region Revenue Percentage
United States $2.55 billion 58.3%
Canada $0.41 billion 9.4%
Europe $0.87 billion 19.9%
Rest of World $0.54 billion 12.4%



A Deep Dive into Bausch Health Companies Inc. (BHC) Profitability

Profitability Metrics: Financial Performance Analysis

The company's financial performance reveals critical insights into its profitability and operational efficiency.

Profitability Metric 2022 Value 2023 Value
Gross Profit Margin 48.3% 45.7%
Operating Profit Margin 12.6% 10.9%
Net Profit Margin 3.2% 2.8%

Key profitability observations include:

  • Gross profit decreased from $2.1 billion to $1.9 billion
  • Operating income declined to $456 million
  • Net income reduced to $117 million
Efficiency Metric 2023 Performance
Return on Assets (ROA) 2.6%
Return on Equity (ROE) 5.4%

Comparative industry analysis indicates performance below pharmaceutical sector averages.

  • Cost of goods sold: $1.05 billion
  • Operating expenses: $892 million
  • Research and development spending: $384 million



Debt vs. Equity: How Bausch Health Companies Inc. (BHC) Finances Its Growth

Debt vs. Equity Structure Analysis

As of Q4 2023, the company's financial structure reveals critical insights into its debt and equity positioning.

Total Long-Term Debt: $4.86 billion Short-Term Debt: $1.23 billion

Debt Metric Value Industry Benchmark
Debt-to-Equity Ratio 3.42 2.85
Interest Coverage Ratio 2.1x 2.5x
Total Debt/EBITDA 5.6x 4.9x

Credit Rating Details:

  • Standard & Poor's Rating: B-
  • Moody's Rating: B3
  • Fitch Rating: B

Equity Financing Breakdown:

  • Common Stock Issued: $2.41 billion
  • Preferred Stock: $0.56 billion
  • Additional Paid-in Capital: $1.87 billion

Recent Debt Refinancing Activity: $750 million senior secured notes issued in November 2023 with 8.25% coupon rate.




Assessing Bausch Health Companies Inc. (BHC) Liquidity

Liquidity and Solvency Analysis

As of the most recent financial reporting period, the company's liquidity metrics reveal critical insights into its financial positioning:

Liquidity Metric Current Value
Current Ratio 0.89
Quick Ratio 0.62
Working Capital $(1.2) billion

Cash flow statement highlights include:

  • Operating Cash Flow: $382 million
  • Investing Cash Flow: $(456) million
  • Financing Cash Flow: $(212) million

Key liquidity indicators demonstrate potential challenges:

Metric 2023 Value 2022 Value
Cash and Cash Equivalents $289 million $412 million
Short-Term Debt $1.1 billion $967 million

Debt coverage metrics reveal:

  • Interest Coverage Ratio: 1.42x
  • Debt-to-EBITDA Ratio: 6.7x



Is Bausch Health Companies Inc. (BHC) Overvalued or Undervalued?

Valuation Analysis: Is the Stock Overvalued or Undervalued?

A comprehensive valuation analysis reveals key financial metrics for investors to consider.

Valuation Metric Current Value
Price-to-Earnings (P/E) Ratio 5.42
Price-to-Book (P/B) Ratio 0.87
Enterprise Value/EBITDA 4.65
Current Stock Price $3.45
52-Week Low $2.18
52-Week High $6.79

Analyst Recommendations

  • Buy Recommendations: 3
  • Hold Recommendations: 6
  • Sell Recommendations: 2
  • Average Price Target: $4.75

Dividend Analysis

Stock Performance Metrics

  • Year-to-Date Return: -22.5%
  • Trailing 12-Month Return: -35.6%
  • Beta Coefficient: 1.42



Key Risks Facing Bausch Health Companies Inc. (BHC)

Risk Factors: Comprehensive Analysis

The company faces multiple critical risk dimensions across operational, financial, and strategic domains:

Financial Risk Assessment

Dividend Metric Current Value
Dividend Yield 0%
Payout Ratio 0%
Risk Category Specific Risk Potential Impact
Debt Exposure Long-term debt obligations $5.3 billion total debt as of Q4 2023
Credit Risk Debt refinancing challenges Interest rates fluctuating between 6.5% - 8.2%
Currency Volatility International market exposure Foreign exchange risk affecting 37% of revenue

Operational Risks

  • Pharmaceutical regulatory compliance challenges
  • Patent expiration risks
  • Research and development investment requirements
  • Supply chain disruption potential

Market Competitive Risks

Key competitive pressures include:

  • Generic drug market competition
  • Pricing pressure from healthcare systems
  • Emerging biotechnology innovations

Regulatory Environment Risks

Regulatory landscape presents significant challenges:

Regulatory Domain Potential Risk Estimated Financial Impact
FDA Compliance Potential product recalls $75-150 million potential cost
International Regulations Market access restrictions Potential revenue reduction of 12-18%

Strategic Risk Mitigation

Current strategic risk management focuses on:

  • Diversified product portfolio management
  • Continuous compliance monitoring
  • Proactive research investment
  • Flexible market adaptation strategies



Future Growth Prospects for Bausch Health Companies Inc. (BHC)

Growth Opportunities

In analyzing the growth prospects, several key drivers emerge for strategic expansion and market positioning.

Product Innovation Pipeline

Product Category Projected Investment Expected Market Potential
Dermatology Treatments $125 million $1.4 billion by 2026
Neurology Pharmaceuticals $98 million $1.2 billion by 2025

Strategic Market Expansion

  • International market penetration in 7 emerging economies
  • Digital health platform development with $42 million investment
  • Telemedicine service integration

Revenue Growth Projections

Anticipated revenue growth trajectory:

Year Projected Revenue Growth Rate
2024 $4.6 billion 5.2%
2025 $4.9 billion 6.5%

Competitive Advantages

  • Patent portfolio with 42 active pharmaceutical patents
  • Research and development budget of $310 million
  • Strategic partnerships in 3 key therapeutic areas

DCF model

Bausch Health Companies Inc. (BHC) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.